Compare JMSB & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMSB | ALEC |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.2M | 275.8M |
| IPO Year | 2022 | 2019 |
| Metric | JMSB | ALEC |
|---|---|---|
| Price | $23.64 | $2.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $23.00 | $4.83 |
| AVG Volume (30 Days) | 58.6K | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ 24.17 | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | $17.09 | $2.03 |
| Revenue Next Year | $10.03 | $29.87 |
| P/E Ratio | $24.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.50 | $1.09 |
| 52 Week High | $24.26 | $3.40 |
| Indicator | JMSB | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 50.36 |
| Support Level | $22.54 | $2.19 |
| Resistance Level | $24.08 | $2.60 |
| Average True Range (ATR) | 0.69 | 0.20 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 56.11 | 27.63 |
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.